Introduction {#s0005}
============

Drug treatment of atrial fibrillation (AF) aims to prevent stroke and restore and maintain sinus rhythm (SR). Experimental and clinical evidence suggest that AF is due to microreentry triggered by ectopic foci located in the proximity of the pulmonary veins[@bib1]; hence, Na^+^ channel blockers (class I) for reducing excitability and K^+^ channel blockers for prolongation of the action potential duration (APD) and effective refractory period (ERP) (class III)[@bib2] are accepted therapeutic options. The multi-ion channel blocker amiodarone is currently the most efficacious antiarrhythmic agent for the pharmacological treatment of AF; nevertheless, the drug is poorly tolerated. Current AF drugs lack atrial specificity, producing proarrhythmic liability in the ventricles that can lead to torsades de pointes and sudden cardiac death.[@bib3] Thus, there is a clear unmet medical need for new pharmacological AF therapies with improved efficacy and safety.[@bib4]

The ultra-rapidly activating delayed-rectifier potassium current (I~Kur~) conducted by the K~v~1.5 protein is a novel drug target because this channel is hardly expressed in ventricles.[@bib5], [@bib6], [@bib7] Therefore, selective inhibitors of I~Kur~ are expected to prolong atrial but not ventricular ERP and should be devoid of risk for ventricular proarrhythmia.

We have previously investigated the electrophysiological effects of several modestly selective I~Kur~ inhibitors, that is, 4-aminopyridine (low concentration), AVE0118, XEN-D0101, and MK-0448, all of which elevated the plateau phase of human atrial action potentials (APs) recorded in trabeculae of right atrial appendages of patients in SR or AF.[@bib8], [@bib9], [@bib10], [@bib11] Interestingly, the expected actions of a K^+^ channel blocker, that is, prolongation of APD/ERP, were observed only in AF preparations, whereas in SR preparations these parameters were shortened.[@bib8], [@bib9], [@bib10], [@bib11] Those experiments were performed with a stimulation frequency of 1 Hz (60 beats/min); however, it is unknown how I~Kur~ inhibitors affect human atrial APs at higher excitation rates as encountered in AF (ie, 228--440 beta/min, 4--8 Hz[@bib12]).

The K~v~1.5 inhibitor MK-0448 failed to affect ERP in young healthy volunteers,[@bib13] and the authors concluded that I~Kur~ block cannot be expected to exert therapeutically useful antiarrhythmic effects in AF. However, only rather long cycle lengths could be tested (≥400 ms, ≤150 beats/min),[@bib13] but like many conventional antiarrhythmic drugs, I~Kur~ inhibitors, too, could exhibit frequency-dependent actions.

We have published a preliminary report that XEN-D0103 (Servier S66913) selectively blocks human I~Kur~ and recombinant hK~v~1.5 current in CHO cells stably expressing the *hKCNA5* gene.[@bib14] Since the effects of I~Kur~ inhibitors on ex vivo human atrial tissue paced at pathophysiological frequencies are unknown, the purpose of this study was to evaluate the effects of XEN-D0103 on atrial APs and ERP at normal and AF relevant frequencies (1--5 Hz) with standard microelectrode techniques in isolated atrial trabeculae from patients in SR and chronic AF (cAF) or paroxysmal AF (pAF). The safety and tolerability of XEN-D0103 were determined in a phase 1 study performed in healthy volunteers.

Methods {#s0010}
=======

Studies reported here conform to the principles outlined in the Declaration of Helsinki and were reviewed and approved by relevant ethics committees; all human subjects gave written informed consent. Atrial tissue was obtained from patients receiving cardiac surgery (ethic committee approval number of TU Dresden: EK790799). The characteristics of the patients are summarized in Online [Supplemental Table S1](#s0110){ref-type="sec"}. The AP study included 22 preparations from patients in SR (SR group), 19 preparations from 17 patients in permanent AF (defined as cAF for \>6 month at the time of tissue collection), and 12 preparations from 11 patients in pAF (episodes of AF terminating spontaneously within 7 days).

In vitro AP and ERP measurements {#s0015}
--------------------------------

APs were measured with a sharp microelectrode (tip resistances 20--80 MΩ) in small pieces of right atrial appendages at 36°C±1°C, as described previously.[@bib9], [@bib11] The basal rate of stimulation was 1 Hz. Each experiment was preceded by a 60-minute equilibration period during which the preparations were allowed to stabilize. Small pieces of the ventricular septum were removed during the surgical correction of outflow track hypertrophy.

A schematic of experimental design for the study of frequency-dependent drug effects is given in [Figure 1](#f0005){ref-type="fig"}. Stimulation frequency was increased in 1-Hz steps up to 5 Hz for 2 minutes each. ERP was measured by an extrastimulus delivered after trains of 10 regular pulses with decreasing intervals in 5-ms steps until the extrastimulus failed to excite. Time-matched control (TMC) experiments in the absence of the drug or in the presence of vehicle (dimethyl sulfoxide \[DMSO\]) were conducted in a similar manner to assess time-dependent changes associated with the length of the experiment ("run-up/run-down"). Since no differences were detected between the 2 groups, the results were pooled.

The following AP parameters were analyzed: resting membrane potential (RMP, in mV); action potential amplitude (APA, in mV); APD at 20%, 50%, and 90% of repolarization (APD~20~, APD~50~ and APD~90~, in ms); maximum rate of depolarization; maximum upstroke velocity (dV/dt~max~, in V/s); and *plateau potential* (defined as the mean absolute membrane potential \[in mV\] in the time window between 20% and 30% of APD~90~ \[PLT~20~\]). Preparations with resting potentials less negative than −65 mV and amplitudes below 85 mV were discarded.

Stock solutions and drug application {#s0020}
------------------------------------

Aliquots of 10 mM XEN-D0103 stock solution (in DMSO) were added directly to the reservoir of the circulating solution. The DMSO concentration never exceeded 0.2%, which did not induce changes when applied alone.

Corrected QT interval evaluation in healthy volunteers {#s0025}
------------------------------------------------------

A double-blind, randomized, placebo-controlled phase 1 single ascending dose study was performed in healthy male volunteers to determine the safety and tolerability of XEN-D0103 and to examine the relationship between the drug plasma concentration and the corrected QT (QTc) interval (for details, see Online [Supplemental Methods](#s0110){ref-type="sec"}). Doses investigated were 10, 30, 60, 120, and 200 mg of XEN-D0103. An assay of plasma XEN-D0103 was performed using a high-performance LC-MS/MS. The lower limit of quantification for the assay was 0.5 ng/mL. Safety electrocardiographic (ECG) telemetry (2-lead ECG) was monitored continuously from dosing until 24 hours after doing to monitor heart function and detect proarrhythmic events in real time.

Statistical analysis {#s0030}
--------------------

For statistical analysis, drug effects on relative AP parameters (ΔERP, ΔAPD~90~, and ΔPLT) were compared with TMCs using an unpaired Student *t* test. Drug effects on absolute AP parameters were compared with predrug effects using a paired Student *t* test (Online [Supplemental Tables S2--S7](#s0110){ref-type="sec"}). Within 1 group, the frequency-dependent changes were analyzed using a repeated-measures analysis of variance (ANOVA) followed by Bonferroni multiple comparison test. Data are typically presented as mean ± standard error of the mean, and 95% confidence intervals are given, where appropriate.

Concentration-effect modeling was performed for QTcF (QT interval corrected by the Fridericia formula) evaluation in healthy volunteers, with ∆∆QTcF intervals being regressed onto the plasma concentrations of XEN-D0103 at the exact times as the continuous 12-lead ECGs. The effect of XEN-D0103 plasma concentration on ∆∆QTcF was investigated using a regression model and ANOVA. At each time of stable supine rest, XEN-D0103 plasma concentration was interpolated using nonparametric superposition. A mixed-effects model that included plasma concentration, treatment group, and an interaction between plasma concentration and treatment group as fixed factors and subject as a random factor was evaluated.

Results {#s0035}
=======

Effects of XEN-D0103 on human cardiac APs and ERP {#s0040}
-------------------------------------------------

APs from patients in SR [Figure 2](#f0010){ref-type="fig"} (upper panel) displayed the typical spike-and-dome shape.[@bib15] The concentration-dependent effects of XEN-D0103 (0.3--10 µM; Online [Supplemental Figure S1](#s0110){ref-type="sec"}) on SR APs at the basal stimulation frequency of 1 Hz showed that XEN-D0103 produced robust effects on electrophysiological parameters, consisting of a prominent elevation of the plateau accompanied by shortening of APD~90~. The maximum effects were reached within 40--50 minutes.

Effects of stimulation frequency on APs and ERP in SR and AF {#s0045}
------------------------------------------------------------

In the absence of the drug, APs and ERP from patients in SR shortened with increasing stimulation rate, as reported by others.[@bib16] This adaptation response was attenuated in AF preparations (Online [Supplemental Figure S2](#s0110){ref-type="sec"}). ERP values and AP parameters (at 1--5 Hz) for SR, cAF, and pAF experiments and TMC experiments are summarized in Online [Supplemental Tables S2--S7](#s0110){ref-type="sec"}. A lager fraction of SR preparations than of AF preparations failed to follow 5 Hz, and since measurements of ERP were more prone to failures than were measurements of other AP parameters, numbers for ERP values are still lower at 4 and 5 Hz.

Effects of XEN-D0103 on APs and ERP in atrial tissue from patients in SR {#s0050}
------------------------------------------------------------------------

In SR preparations, the ERP/APD~90~ shortening effect of XEN-D0103 (3 µM) at 1 and 2 Hz was converted into a significant prolonging effect at 3 and 4 Hz ([Figure 2](#f0010){ref-type="fig"}, upper panel, and [Figure 3](#f0015){ref-type="fig"}) and excitability was suppressed in the presence of the drug at 5 Hz.

Although the typical "spike-and-dome" shape of the SR AP converted to a triangular AF-like shape at 4 Hz, the maximum effect of XEN-D0103 on the plateau potential (ΔPLT~20~, [Figure 3](#f0015){ref-type="fig"}, lower left panel) was similar at all frequencies while APD~20~ and APD~50~ were both significantly prolonged at all frequencies tested. RMP was not altered by XEN-D0103 (see Online [Supplemental Table S2](#s0110){ref-type="sec"}); however, a reduction in dV/dt~max~ was observed.

The results of TMC experiments revealed a trend toward shortening of APD~90~ over the course of the experiment, as such the drug-induced prolongation of APD~90~ at 3 and 4 Hz is likely to be underestimated and the shortening of APD~90~ at lower pacing frequencies of 1 and 2 Hz may be overestimated. Data were not corrected for run-down because experiments were conducted in different tissue preparations.

Effects of XEN-D0103 on APs and ERP in atrial tissue from patients in cAF {#s0055}
-------------------------------------------------------------------------

In cAF trabeculae, XEN-D0103 also significantly elevated the PLT~20~ ([Figure 2](#f0010){ref-type="fig"}, middle panel). The increase in PLT~20~ was smaller compared to SR preparations and somewhat decreased with increasing stimulation frequencies ([Figure 4](#f0020){ref-type="fig"}), but in contrast to SR, XEN-D0103 prolonged APD at the 3 repolarization levels analyzed (prolongation statistically significant for APD~90~ at 2 Hz and for APD~50~ and APD~20~ at all frequencies tested) (Online [Supplemental Table S4](#s0110){ref-type="sec"}). APA was significantly increased at 1 Hz; RMP was significantly more negative at 1--4 Hz; and dV/dt~max~ was similar in the absence and presence of the drug at all frequencies (Online [Supplemental Table S4](#s0110){ref-type="sec"}).

With 3 µM XEN-D0103, ERP was significantly prolonged at all frequencies but only reached statistical significance at 2 Hz ([Figure 4](#f0020){ref-type="fig"}, left upper panel, and Online [Supplemental Table S4](#s0110){ref-type="sec"}). Similar to the results in SR tissue, ERP and APD~90~ shortened with time in TMC experiments (Online [Supplemental Table S5](#s0110){ref-type="sec"}), as such leading to the underestimation of drug effects on ERP and APD~90~.

Effects of XEN-D0103 on APs and ERP in atrial tissue from patients in pAF {#s0060}
-------------------------------------------------------------------------

The APs recorded from pAF tissue displayed a spike-and-dome shape similar to that seen in SR tissue ([Figure 2](#f0010){ref-type="fig"}, lower panel). In pAF tissue, XEN-D0103 (3 µM) produced frequency-dependent effects similar to those in SR tissue ([Figure 5](#f0025){ref-type="fig"}). APA and RMP were not affected by XEN-D0103, but dV/dt~max~ was reduced in the presence of XEN-D0103 at 1--4 Hz (*P* \< .05; Online [Supplemental Table S6](#s0110){ref-type="sec"}). PLT~20~ was elevated at all frequencies, and APD~90~ was shortened at 1 Hz and even slightly prolonged at 5 Hz ([Figure 5](#f0025){ref-type="fig"}). In the presence of the drug, only 4 and 1 of 6 preparations could be stimulated at 4 and 5 Hz, respectively (Online [Supplemental Table S6](#s0110){ref-type="sec"}), similar to SR tissue, whereas 5 and 3 of 6 trabeculae followed these rates in TMC (Online [Supplemental Table S7](#s0110){ref-type="sec"}).

ERP significantly decreased in pAF tissue at the stimulation frequency of 1 Hz. This effect was diminished at 2 Hz and turned into a slight, though nonsignificant, prolongation at 3 and 4 Hz. In TMC pAF preparations, ERP tended to shorten from 1 to 4 ([Figure 5](#f0025){ref-type="fig"} and [Table S7](#s0110){ref-type="sec"}).

Effects of XEN-D0103 on human ventricular AP parameters {#s0065}
-------------------------------------------------------

For comparison purposes and for confirming the atrial selectivity of XEN-D0103, APs were recorded from 3 human ventricular septum preparations. XEN-D0103 (10 µM) had no significant effect on human ventricular AP parameters (Online [Supplemental Figure S3](#s0110){ref-type="sec"}).

Effects of XEN-D0103 on the QTc interval and drug-induced proarrhythmia in healthy human subjects {#s0070}
-------------------------------------------------------------------------------------------------

Comprehensive ECG recordings and ECG analysis were performed in a phase 1 clinical trial to determine whether XEN-D0103 prolongs the QTc interval in humans. As no meaningful change in heart rate (HR) was noted during the study, the Fridericia formula was used to correct the QT interval for the HR (QTcF). A plot of XEN-D0103 plasma concentration vs ∆∆QTcF is shown in [Figure 6](#f0030){ref-type="fig"}, and most notably, XEN-D0103 plasma concentrations reached 7000 ng/mL in some volunteers without increasing ∆∆QTc. A categorical analysis of QT interval and QTcF was performed, and no subjects receiving an active treatment had a QT interval or QTcF \>450 ms, or increase in QTcF from baseline \>30 ms. In addition to 12-lead Holter monitoring, 2-lead ECG telemetry monitoring was performed for 24 hours after dosing. All results of ECG telemetry were considered as normal by the investigator. There were no clinically significant changes, including induction of AF or ventricular proarrhythmia after XEN-D0103 dosing. No dose-related effects on PR interval, QRS complex, and HR as well as on T-wave and U-wave morphologies were noted.

Discussion {#s0075}
==========

We have investigated the effects of the novel highly selective I~Kur~/K~v~1.5 inhibitor XEN-D0103 (Servier S66913) on AP parameters and ERP over a pathophysiological relevant range of frequencies (1--5 Hz). Our major finding was that XEN-D0103 prolonged APD and ERP preferentially at high stimulation rates in SR and pAF preparations, providing novel mechanistic information on modulating I~Kur~ that is likely to be highly desirable for treating pAF.

In accordance with the literature,[@bib15], [@bib17], [@bib18] electrical remodeling during cAF caused triangulation of the AP shapes. Atrial tissue from patients in pAF was apparently not electrically remodeled since APs still exhibited the typical SR-like spike-and-dome configuration. We also found that atrial APD and ERP shortened with increasing frequency of stimulation, which has been related mainly to decrease in L-type Ca^2+^ current,[@bib19] and that adaptation to high rates was attenuated in preparations from patients in cAF.[@bib15], [@bib16] The maximum rate of depolarization dV/dt~max~ declined significantly at high rates[@bib16] because of the incomplete restoration of RMP with an increasing number of preparations failing to capture stimulation, thereby limiting frequency testing to 5 Hz.

Channels conducting the human cardiac I~Kur~ are encoded by the K~v~1.5 gene *KCNA5*, which is strongly expressed in atria, and although small amounts of messenger RNA have been reported in human ventricular tissue, no functional current has been reported.[@bib20] Consequently, I~Kur~ block exhibits an atrial-selective effect on cardiac repolarization and could be considered a drug intervention suited for the treatment of atrial rhythm disturbances without unwanted effects on ventricular function. This is suggested by the lack of impact of XEN-D0103 on ventricular AP. The absence of XEN-D0103--induced QTc prolongation as well as PR and QRS changes and the absence of arrhythmias, including AF, in healthy volunteers observed in the clinical study confirms the finding previously reported for XEN-D0101[@bib9] and MK-0448[@bib13] and also provides further support for I~Kur~ only being present and functional in the human atria and not the ventricle.

The characteristic changes in electrophysiological parameters observed with XEN-D0103 in human right atrial trabeculae (1 Hz) are consistent with block of K~v~1.5 channels as previously reported for this[@bib14] and other less selective drugs (eg, 4-AP,[@bib7], [@bib21], [@bib22] DPO-1,[@bib23] AVE0118,[@bib8] XEN-D0101,[@bib9] and MK-0448[@bib10]). These drugs elevated the plateau potential in SR preparations and significantly shortened APD~90~ at 1 Hz but prolonged APD~90~ in cAF trabeculae. The shortening of APD~90~ and ERP by K~v~1.5 inhibitors in SR is proposed to be caused by the marked elevation of the plateau potential into a voltage range where more hERG channels are activated, and although they inactivate rapidly, they can recover from inactivation at more negative potentials and thus hasten final repolarization.[@bib24] Since the most prominent effects of XEN-D0103 were elevation of PLT~20~, shortening of APD~90~ in SR at 1 Hz, and prolongation of APD~20~, APD~50~, APD ~90~ in cAF, we conclude that XEN-D0103 does block I~Kur~ in human atrial trabeculae. Furthermore, these characteristic electrophysiological changes appear to be a dominant class effect of I~Kur~ block, since they are observed with XEN-D0103 as well as with other less selective K~v~1.5 inhibitors.

Interestingly, in SR preparations, the APD shortening effect of XEN-D0103 at the basal frequency of 1 Hz turns into an APD-prolonging effect accompanied by an increase in ERP at the higher stimulation rates of 3 and 4 Hz ([Figure 3](#f0015){ref-type="fig"}). In addition, fewer preparations could be stimulated at 4 Hz and excitation failed in all SR preparations at 5 Hz in the presence of XEN-D0103. In pAF, similar effects were observed, the PLT~20~ increased at all frequencies, and ERP was prolonged at 3--4 Hz (although this effect was significant only at 3 Hz) with all but one preparation failing to capture excitation at 5 Hz. These qualitatively similar responses suggest that tissue from patients in SR may be a useful surrogate for investigating the effects of drugs in pAF, especially given the scarcity of tissue from patients in pAF. The data in SR and pAF tissue provide novel evidence in support of I~Kur~/K~v~1.5 as a target for the management of pAF.

In cAF, qualitatively different effects were observed compared with those seen in SR and pAF. All but one preparation followed stimulation at 5 Hz both in the absence and in the presence of XEN-D0103. The ability to pace the cAF tissue at high frequencies suggests a remodeled phenotype that forms the substrate for the initiation and perpetuation of the arrhythmia in these patients. The shorter APD~90~ and ERP and the more negative RMP of cAF tissue have previously been reported by us and others[@bib9], [@bib11], [@bib16], [@bib25], [@bib26], [@bib27], [@bib30] at 1 Hz. This is likely to contribute to the ability of cAF tissue to capture higher stimulation frequencies, in the absence and presence of the drug, than to the ability of SR or pAF tissue because of the higher availability of Na^+^ channels at more negative membrane potential. In cAF tissue, XEN-D0103 prolonged the APD at all frequencies but effects on the ERP were significant only at 2 Hz. However, the TMC data suggest this was underestimated at all frequencies tested. Despite these effects on AP parameters in cAF preparations, we do not expect block of Kv1.5 channels by XEN-D0103 to *convert* cAF back to SR because of electrical and structural remodeling.[@bib6] Nevertheless, this effect may protect the atrial myocardium during the phase of reverse remodeling after cardioversion.

At present, it is not known whether and how block of I~Kur~ is related to ERP. We speculate that the primary reduction in I~Kur~ can cause a secondary effect on Na^+^ conductance, leading to increased postrepolarization refractoriness rather than having a direct effect on the cardiac Na^+^ channel. This is supported by the lack of effect on the recombinant peak Na~v~1.5 current at concentrations up to 10 μM.[@bib14] Given the lack of a direct effect on Na^+^ channels, the increase in postrepolarization refractoriness [@bib28], [@bib29] may be due to an indirect effect on Na^+^ channel availability owing to the marked change in the profile of the AP in the presence of the drug (ie, elevated plateau and triangulation of the AP shapes). However, this is speculative and further experiments are needed to clarify the mechanism of ERP modulation by XEN-D0103, but these are outside the scope of the present study. In any case, it is seems highly desirable to increase ERP in both SR and pAF to disrupt reentry and prevent AF recurrence. This, in turn, may be expected to facilitate the reverse remodeling process after cardioversion. Pharmacological interventions for interrupting microreentry have to prolong the ERP, while suppression of ectopic foci requires reduction of excitability. Given the pharmacological profile of XEN-D0103, it is more likely to increase atrial refractoriness than to reduce excitability.

It should be noted that although the reported effect of XEN-D0103 in cAF appears small, prolongation of ERP may be underestimated because of the concomitant reduction of ERP observed in TMC. A broader comparison to other AF antiarrhythmic drugs was not possible, as they would require evaluation using the methodology that evaluated APD parameters and ERP in SR and AF tissue at multiple pacing frequencies as well as assessment of the effect on ventricular tissue to confirm atrial selectivity. More importantly, the present data suggest some benefits of XEN-D0103 in pAF. A lack of effect of other I~Kur~ inhibitors in healthy volunteers[@bib13] could be due to the rather long cycle lengths (ie, \>400 ms) used. According to our data, we would not have expected a prolonging effect of MK-0448 on atrial ERP at cycle lengths below 333 ms (3 Hz). Last but not least, although I~Kur~ had been originally discovered in dog atria, I~Kur~ could no longer be demonstrated during the past years[@bib31]; hence, the absence of any effect of I~Kur~ inhibitors in dog models of AF is not surprising. In conclusion, we found the use of I~Kur~ inhibitors in treating AF that includes both pAF and recent-onset persistent AF, that is, AF of \<6 months of duration.

Our data highlight the importance of pathophysiologically relevant pacing frequencies (SR and pAF) and an arrhythmogenic substrate (ionic and structural remodeling in cAF). Only at higher pacing frequencies in SR and pAF and at 2 and 3 Hz in cAF tissue did we observe significant increases in APD/ERP. On the basis of our results, we expect XEN-D0103 to be preferentially effective in non-remodeled atrial tissue (SR and pAF). The positive frequency dependence of ERP prolongation and loss of excitability at high frequencies (5 Hz) in SR preparations and an essentially similar pattern of effects in pAF suggest that I~Kur~ inhibitors could be effective for the termination of recent-onset AF (ie, suppression of high-frequency firing) and reduction of AF burden in pAF before electrical and structural remodeling has taken place.

To date, no clinical trials have been published on a selective human I~Kur~ inhibitor in a patient population with AF; however, based on these novel mechanistic findings for XEN-D0103, it is currently being evaluated in 2 phase 2 clinical studies to evaluate the therapeutic potential of a selective I~Kur~ inhibitor to prevent recurrences in patients in pAF. They both started in 2014.

The first trial (EudraCT no. 2013-004456-38) was a double-blind, randomized, placebo-controlled, crossover study assessing a single-dose level (150 mg twice daily) of XEN-D0103 in patients in pAF and patients with implanted pacemakers. The primary objective was to assess the reduction in AF burden over 28 days compared to placebo. The second phase 2 study in patients in pAF called DIAGRAF-IKUR (EudraCT no. 2013-004456-38) aimed to evaluate the efficacy of 3 doses of XEN-D0103 (S66913), vs placebo on AF and/or atrial tachycardia burden (AF/AT burden) in patients who have an indication for AF ablation and are implanted with insertable cardiac monitoring device.

Study limitations {#s0080}
-----------------

In most of the preparations, basic parameters slightly declined with time. The classification of patients into SR and AF groups is not always reliable; that is, the SR group may include atrial tissue from patients that have had unrecognized episodes of pAF or recent-onset AF. Furthermore, cAF tissue will include patients in permanent AF who are known to be refractory to SR-maintenance therapy.

Conclusion {#s0085}
==========

The selective I~Kur~ inhibitor XEN-D0103 consistently elevated the AP plateau in human atrial trabeculae irrespective of the initial shapes of the control APs and whether the preparations originated from patients in SR, pAF, or cAF. In SR and pAF preparations, the APD shortening effect observed at 1 Hz resulted in prolongation of APD~90~ and ERP at high stimulation rates with loss of excitability at 5 Hz, whereas in cAF preparations, ERP prolongation was modest. For the prevention of AF recurrence, frequency-dependent prolongation of ERP by XEN-D0103 in both SR and pAF preparations is a highly desirable mode of action that may protect the atrial myocardium during the phase of reverse remodeling after cardioversion. These data warrant the evaluation of XEN-D0103 in a clinical trial in patients in pAF.

Clinical PerspectivesPharmacological treatment of atrial fibrillation (AF) remains a clinical challenge owing to the lack of effective and safe drugs. The selective blockers of K~v~1.5 channels were designed to fill this gap, yet their antiarrhythmic effects are yet to be reported in a clinical setting. To date, most K~v~1.5 blockers have been shown to prolong only action potential duration (APD) and effective refractory period (ERP) at physiological beating rates in atrial tissue remodeled by persistent AF, whereas they actually *shorten* APD and ERP in sinus rhythm (SR) tissue. However, little is known about their efficacy at the high rates of excitation encountered during AF. Here we report that the highly selective K~v~1.5 channel blocker XEN-D0103 prolongs APD and ERP measured with sharp microelectrodes in human right atrial trabeculae from patients in chronic AF in the frequency range 1--5 Hz. In trabeculae from patients in SR and paroxysmal AF, the ADP-shortening effect of XEN-D0103 at low stimulation rate (1 Hz) turns into APD prolongation at high rates, leading to failure of excitation response. We conclude that the XEN-D0103 exhibits positive frequency--dependent electrophysiological effects that could be clinically useful, because prolongation of APD and suppression of action potentials by XEN-D0103 at high stimulation rates in SR and paroxysmal AF tissue is expected to reduce AF burden. This concept needs to be confirmed in clinical trials. Our data cannot provide evidence for preventing recurrence or termination of permanent AF by XEN-D0103. This must be tested in appropriate models.

Appendix {#s0105}
========

Supplementary materials {#s0110}
-----------------------
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![Schematic of the experimental procedure for action potential measurements in human atrial trabeculae. **A:** Time-matched control experiments: after an equilibration period of ≥60 minutes at a stimulation rate of 1 Hz, the effective refractory period was measured (b). Stimulation rate was then increased successively, with 2 minutes for stabilization (a) and 2 minutes for the measurement of effective refractory period (b). **B:** After returning to 1 Hz, preparations were exposed to XEN-D0103 for 60 minutes before going through another set of rate increases.](gr1){#f0005}

![Frequency dependence of XEN-D0103 effects (3 µM). Original traces of action potentials recorded in right atrial trabeculae from patients in sinus rhythm (SR), chronic atrial fibrillation (cAF), and paroxysmal AF (pAF). c, Predrug control; red line, in the presence of XEN-D0103. The red dashed line in the top-right panel indicates failure to follow stimulation at this rate in the presence of the drug. Calibration bars as indicated.](gr2){#f0010}

![Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in sinus rhythm (SR). Effects on effective refractory period (ERP), action potential duration at 90% repolarization (APD~90~), and plateau potential (defined as the mean absolute membrane potential \[in mV\] in the time window between 20% and 30% of APD~90~ \[PLT~20~\]) depicted as the difference between predrug control and in the presence of the drug (delta values). Note that in SR, *none* of the preparations followed stimulation at 5 Hz in the presence of XEN-D0103. Separate time-matched control (TMC) experiments without drug application are shown on the right side. Delta values in the presence of the drug were compared with the corresponding TMC data at each frequency using an unpaired Student *t* test. The results of this comparison are shown as ^\#\#^*P* \< .01 and ^\#\#\#^*P* \< .0001. Delta values at each frequency (1--3 Hz) in the presence of the drug were compared in a group to determine frequency-dependent drug effects using a repeated-measures analysis of variance (results shown as a line, comparing 1--3 Hz) with a Bonferroni posttest (results shown in the inset). Failure to capture action potentials in all preparations at 5 Hz precluded comparison of this group using a repeated-measures test.](gr3){#f0015}

![Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in chronic atrial fibrillation (cAF). Layout as in [Figure 3](#f0015){ref-type="fig"}. Delta values in the presence of the drug were compared with the corresponding time-matched control data at each frequency using an unpaired Student *t* test. The results of this comparison are shown as ^\#^*P* \< .05 and ^\#\#\#^*P* \< .0001. Note that repeated-measures analysis of variance with Bonferroni posttest did not result in any statistically significant differences between 1, 2, and 3 Hz. Abbreviations as in [Figure 3](#f0015){ref-type="fig"}.](gr4){#f0020}

![Frequency-dependent effects of XEN-D0103 in right atrial trabeculae from patients in paroxysmal atrial fibrillation (pAF). Layout as in [Figure 3](#f0015){ref-type="fig"}. Delta values in the presence of the drug were compared with the corresponding time-matched control data at each frequency using an unpaired Student *t* test. The results of this comparison are shown as ^\#^*P* \< .05, ^\#\#^*P* \< .01, and ^\#\#\#^*P* \< .0001. Group comparison of delta values (1--3 Hz) in the presence of the drug as in [Figure 3](#f0015){ref-type="fig"}. Abbreviations as in [Figure 3](#f0015){ref-type="fig"}.](gr5){#f0025}

![Baseline- and placebo-adjusted QTcF (∆∆QTcF) values plotted against XEN-D0103 plasma concentration derived from healthy volunteers (n = 63). Concentration effect modeling showed no evidence of a relationship between the plasma concentration of XEN-D0103 (in ng/mL) and ∆∆QTcF (in ms) in healthy volunteers orally dosed with XEN-D0103. QTcF = QT interval corrected by the Fridericia formula.](gr6){#f0030}
